ANAB Logo

AnaptysBio, Inc. (ANAB) 

NASDAQ
Market Cap
$677.65M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
38 of 774
Rank in Industry
32 of 433

Largest Insider Buys in Sector

ANAB Stock Price History Chart

ANAB Stock Performance

About AnaptysBio, Inc.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable …

Insider Activity of AnaptysBio, Inc.

Over the last 12 months, insiders at AnaptysBio, Inc. have bought $10M and sold $5.58M worth of AnaptysBio, Inc. stock.

On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $24.14M and sold $6.1M worth of stock each year.

Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $60M.

The last purchase of 273,972 shares for transaction amount of $10M was made by EcoR1 Capital, LLC (10 percent owner) on 2024‑08‑14.

List of Insider Buy and Sell Transactions, AnaptysBio, Inc.

2024-09-23SaleChief Medical Officer
1,500
0.0054%
$38.67$58,005-11.02%
2024-09-17SaleCHIEF LEGAL OFFICER
3,780
0.0128%
$38.41$145,191-14.20%
2024-09-16SaleChief Medical Officer
2,220
0.0074%
$38.93$86,425-16.45%
2024-09-16SaleCHIEF LEGAL OFFICER
8,720
0.0297%
$39.82$347,270-16.45%
2024-09-16SaleCHIEF FINANCIAL OFFICER
12,220
0.0417%
$39.91$487,725-16.45%
2024-08-14SaleChief Medical Officer
2,000
0.0088%
$40.00$80,0000.00%
2024-08-14Purchase10 percent owner
273,972
1.095%
$36.50$10M0.00%
2024-07-18SaleChief Medical Officer
1,500
0.0056%
$35.00$52,500+0.84%
2024-07-15Saledirector
10,000
0.0463%
$30.64$306,4220.00%
2024-06-21Saledirector
1,950
0.007%
$23.17$45,182+43.58%
2024-06-18Saledirector
1,950
0.007%
$23.16$45,162+50.50%
2024-05-22SaleCHIEF FINANCIAL OFFICER
1,500
0.0052%
$23.72$35,580+32.36%
2024-03-25SaleCEO
3,000
0.0114%
$21.42$64,268+19.38%
2024-03-22SaleCEO
145,940
0.5734%
$22.78$3.33M+15.64%
2024-02-16SaleCHIEF LEGAL OFFICER
5,000
0.0195%
$25.00$125,000+4.02%
2024-01-30SaleCHIEF FINANCIAL OFFICER
3,065
0.0114%
$23.63$72,425+3.61%
2024-01-08SaleCEO
6,866
0.0251%
$21.81$149,747+7.09%
2024-01-08SaleChief Medical Officer
2,554
0.0093%
$21.81$55,703+7.09%
2024-01-08SaleChief Financial Officer
2,180
0.008%
$21.81$47,546+7.09%
2024-01-08SaleChief Legal Officer
2,305
0.0084%
$21.81$50,272+7.09%

Insider Historical Profitability

29.1%
EcoR1 Capital, LLC10 percent owner
7794996
25.6172%
$22.27100+15.76%
NODELMAN OLEG
7521024
24.7169%
$22.2711+12.85%
Novo Holdings A/S10 percent owner
1936604
6.3644%
$22.2718+58.88%
Topper James N
1045031
3.4344%
$22.2710+58.88%
Frazier Healthcare V, LP10 percent owner
311291
1.023%
$22.2710+58.88%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$169.37M27.537.52M0%+$01.19
BlackRock$38.74M6.31.72M-4.43%-$1.8M<0.01
The Vanguard Group$30.49M4.961.35M-1.89%-$588,042.23<0.01
Tang Capital Management, LLC$29.97M4.871.33M-31.77%-$13.96M0.11
Boxer Capital, LLC$29.28M4.761.3M0%+$00.6
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.